Antisense c-mycRetroviral Vector Suppresses Established Human Prostate Cancer
- 20 March 1998
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 9 (5) , 747-755
- https://doi.org/10.1089/hum.1998.9.5-747
Abstract
Prostate cancer eventually becomes androgen resistant, resumes growth, and kills the patient. Characterization of genetic events that lead to androgen refractory prostatic neoplasia has revealed the frequent overexpression of c-myc and uncontrolled prostate cancer proliferation. A novel strategy to combat advanced prostate cancer utilized a replication incompetent retrovirus that contained the mouse mammary tumor virus (MMTV) promoter within the retroviral vector to allow transcription of antisense c-myc gene within target prostate tumor cells. The transduction of cultured DU145 cells by XM6:MMTV-antisense c-myc RNA retrovirus did not affect cell proliferation in culture, yet a single direct injection of MMTV-antisense c-myc viral media into established DU145 tumors in nude mice produced a 94.5% reduction in tumor size compared to tumors treated with control virus MTMV sense fos and untreated tumor by 70 days. Two animals in the antisense c-myc-treated group had complete regression of their tumors. Histopathological examination of the tumors revealed that MMTV-antisense c-myc-transduced DU145 tumors had increased tumor cell differentiation, decreased invasion, and a marked stromal response. The mechanism for the antitumor effect of MMTV-antisense c-myc retrovirus appears to be suppression of c-myc mRNA and protein, and decreased bcl-2 protein. The in vivo transduction of prostate cancer cells with MMTV-antisense c-myc retroviruses reduced tumor growth by suppressing c-myc, resulting in the down-regulation of bcl-2 protein. Consequently, the MMTV-antisense c-myc retrovirus may be useful for gene therapy against advanced, hormone-refractory prostate cancer. Advanced prostate cancer over-expresses c-myc. A novel strategy to combat advanced prostate cancer utilized a replication-incompetent retrovirus which contained a mouse mammary tumor virus (MMTV) promoter to express antisense c-myc in prostate cells. Direct injection of MMTV-antisense c-myc virus into established DU145 tumors in nude mice produced a 94.5% reduction in tumor size compared to controls by 70 days. MMTV-antisense c-myc-transduced DU145 tumors had increased differentiation, stromal response, and apoptosis and decreased invasion. MMTV-antisense c-myc retrovirus appears to mediate its antitumor effects by suppressing c-myc, which is associated with a decreased bcl-2 protein.Keywords
This publication has 22 references indexed in Scilit:
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- The role of c-myc in cell growthCurrent Opinion in Genetics & Development, 1993
- Apoptotic cell death induced by c-myc is inhibited by bcl-2Nature, 1992
- Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitroMolecular Endocrinology, 1992
- Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic miceCell, 1990
- The regulation of expression of mouse mammary tumor virus DNA by steroid hormones and growth factorsJournal of Steroid Biochemistry, 1989
- Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organCell, 1989
- Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma systemThe Prostate, 1988
- Enhanced expression of the c‐myc protooncogene in high‐grade human prostate cancersThe Prostate, 1987
- Expression of cellular oncogenes in human prostatic carcinoma cell linesBiochemical and Biophysical Research Communications, 1985